Diagnostic value of serum tumor markers in bone metastasis of non-small cell lung cancer

doi:10.3760/cma.j.issn.1673-422X.2018.06.004

Abstract

Abstract: Objective To analyze the diagnostic value of serum tumor markers in bone metastasis of non-small cell lung cancer (NSCLC). Methods The clinical data and follow up data of 160 patients with NSCLC from March 2013 to September 2015 in Tangshan People′s Hospital were retrospectively analyzed. According to the status of bone metastasis, the patients were divided into the observation group with bone metastasis (n=114) and the control group without bone metastasis (n=46). The positive rates and concentrations of 4 tumor markers including carcinoembryonic antigen (CEA), carbohydrate antigen CA125, CA19-9 and Ferritin were analyzed and compared. And their sensitivities and specificities to the diagnosis of NSCLC bone metastasis were analyzed. The Youden index was calculated to capture the performance of the diagnostic test. Results The concentrations of CEA, CA125, CA19-9 and Ferritin in the observation group were (19.74±6.71) μg/L, (45.62±19.53) kU/L, (35.89±15.66) kU/L and (334.02±79.43) μg/L respectively, which were higher than those in the control group ［(2.36±0.92) μg/L, (14.37±5.43) kU/L, (15.31±7.22) kU/L, (122.58±69.46) μg/L］, and the differences were statistically significant (t=7.200, P＜0.001; t=7.180, P＜0.001; t=6.032, P＜0.001; t=11.152, P＜0.001). The positive rates of CEA, CA125, CA19-9 and Ferritin in the observation group were 78.95%, 68.42%, 52.63% and 73.68% respectively, which were higher than those in the control group (8.70%, 4.35%, 4.35% and 13.04%), and the differences were statistically significant (χ2=66.746, P＜0.001; χ2=53.822, P＜0.001; χ2=32.193, P＜0.001; χ2=48.975, P＜0.001). The sensitivities of CEA, CA125, CA199 and Ferritin were 78.94%, 68.42%, 52.63% and 73.68% respectively, and the specificities of them were 91.30%, 95.65%, 95.65% and 86.96% respectively. The Youden indexes were 70.24%, 64.07%, 48.28% and 60.64% respectively. The sensitivity and specificity of multifactorial combination were 99.17% and 72.63%, and the Youden index was 71.80%. Conclusion Four tumor markers including CEA, CA125, CA19-9 and Ferritin were correlated with NSCLC, and combined detection has better performance of dignosis than single factor.

Key words: Carnicoma, non-small cell lung, Tumor markers, biological, Neoplasm metastasis, Diagnosis

Wu Qiong, Ma Haiyang, Wang Xuechen, Zhang Mingming, Zhang Yong. Diagnostic value of serum tumor markers in bone metastasis of non-small cell lung cancer[J]. Journal of International Oncology, 2018, 45(6): 337-340.

References

［1］屈若祎, 周宝森. 2004—2010年中国肺癌死亡分布及趋势分析［J］. 中国卫生统计, 2014, 31(6): 932-935. ［2］姚舒洋, 王鑫, 李小雪, 等. 非小细胞肺癌首发骨转移患者的临床特征、治疗及预后分析［J］. 首都医科大学学报, 2015, 36(4): 533-536. DOI: 10.3969/j.issn.1006-7795.2015.04.004. ［3］孙燕, 管忠震, 廖美琳, 等. 肺癌骨转移诊疗专家共识(2014版)［J］. 中国肺癌杂志, 2014, 17(2): 57-72. DOI: 10.3779/j.issn.1009-3419.2014.02.01. ［4］郭庆志, 吴梅娜, 安彤同, 等. 322例非小细胞肺癌骨转移临床特点及治疗的回顾性分析［J］. 中国肺癌杂志, 2014, 17(9): 656-662. DOI: 10.3779/j.issn.1009-3419.2014.09.03. ［5］支修益, 姚舒洋. 肿瘤标志物在肺癌患者管理中的研究进展［J］. 首都医科大学学报, 2015, 36(6): 986-991. DOI: 10.3969/j.issn.1006-7795.2015.06.028. ［6］叶骉飞, 郑平菊, 张妮, 等. 肺癌骨转移临床特征及预后相关因素［J］. 实用医学杂志, 2016, 32(10): 1656-1659. DOI: 10.3969/j.issn.1006-5725.2016.10.031. ［7］赵艳萍, 邱艳芳, 朱丽娜, 等. 单光子发射断层成像与磁共振成像诊断不同病理类型肺癌骨转移的价值［J］. 中国老年学杂志, 2015, 35(13): 3658-3659. DOI: 10.3969/j.issn.1005-9202.2015.13.081. ［8］王英, 李佩章, 朱波, 等. 应用Logistic回归和ROC曲线综合评价肿瘤标志物联合检测对肺癌的诊断价值［J］. 中国现代医学杂志, 2015, 25(19): 47-50. ［9］郭柳薇, 高兴华, 黄王莹, 等. 肺癌患者6种血清肿瘤标志物检测结果分析［J］. 江苏医药, 2014, 40(1): 69-71. DOI: 10.19460/j.cnki.02533685.2014.01.025. ［10］蒋贝兰, 沙杭. 肺癌血清肿瘤标志物的研究现状及进展［J］. 天津医药, 2014, 42(4): 393-395. DOI: 10.3969/j.issn.02539896.2014.04.029. ［11］汪广杰, 王东, 张涛, 等. 血清多种肿瘤标志物联合检测对肺癌的诊断价值［J］. 重庆医学, 2015, 44(13): 1759-1761. DOI: 10.3969/j.issn.1671-8348.2015.13.011. ［12］李宏宇, 李沛, 蔡三立, 等. 血清CEA、NSE、CYFRA211在肺癌诊治及预后判断中的临床价值［J］. 中国老年学杂志, 2015, 35(22): 6458-6459. DOI: 10.3969/j.issn.10059202.2015.22.068. ［13］张炜, 郭万华. 99mTcMDP全身骨扫描和血清CEA、NSE、CYFR21-1、CA125测定对小细胞肺癌骨转移的临床评价［J］. 东南大学学报: 医学版, 2015, 34(6): 881-885. DOI: 10.3969/j.issn.1671-6264.2015.06.005. ［14］ Ji M, Li XD, Shi HB, et al. Clinical significance of serum ferritin in elderly patients with primary lung carcinoma［J］. Tumour Biol, 2014, 35(10): 10195-10199. DOI: 10.1007/s13277-014-2317-y.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[3]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[4]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[5]	Chen Qi, Xu Chenyang, Wang Yin, Lei Dapeng. Current application status of hyperspectral imaging in the diagnosis and treatment of head and neck tumor [J]. Journal of International Oncology, 2024, 51(5): 298-302.
[6]	Zhang Lili, Tan Ru, Fang Xueli, Yang Yu, Sang Zheng, Li Baosheng. Imaging diagnosis， pathological upgrade， and imaging technology progress of ductal carcinoma in situ of the breast [J]. Journal of International Oncology, 2024, 51(3): 166-169.
[7]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing. Progress of radiotherapy in oligometastatic non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(3): 170-174.
[8]	Peng Qin, Cai Yuting, Wang Wei. Advances on KPNA2 in liver cancer [J]. Journal of International Oncology, 2024, 51(3): 181-185.
[9]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan. Research progress on the histopathological growth patterns of colorectal liver metastasis [J]. Journal of International Oncology, 2024, 51(2): 114-118.
[10]	Jin Xudong, Chen Zhongjian, Mao Weimin. Research progress on the role of MTAP in malignant mesothelioma [J]. Journal of International Oncology, 2024, 51(2): 99-104.
[11]	Huang Zhen, Chen Yongshun. Research progress of circulating tumor DNA in the diagnosis and treatment of hepatocellular carcinoma [J]. Journal of International Oncology, 2024, 51(1): 59-64.
[12]	Wang Jing, Xu Wenting. Value of NLR， CEA combined with coagulation indicators in the differential diagnosis of benign and malignant breast nodules with a diameter ≤ 1.0 cm [J]. Journal of International Oncology, 2023, 50(9): 520-526.
[13]	Zhang Lu, Jiang Hua, Lin Zhou, Ma Chenying, Xu Xiaoting, Wang Lili, Zhou Juying. Analysis of curative effect and prognosis of immune checkpoint inhibitor in the treatment of recurrent and metastatic cervical cancer [J]. Journal of International Oncology, 2023, 50(8): 475-483.
[14]	Shandong Medical Association Multidisciplinary Joint Committee on Lung Cancer. Shandong Provincial Medical Association multidisciplinary standardized diagnosis and treatment guidelines for esophageal carcinoma （2023 Edition） [J]. Journal of International Oncology, 2023, 50(7): 385-397.
[15]	Ju Yifan, Xu Chenyang, Lei Dapeng. Research progress of pathomics in head and neck neoplasms [J]. Journal of International Oncology, 2023, 50(5): 294-298.